根据第 8 版美国癌症联合委员会 (AJCC) 分类的预后分期，分析眼睑和眼周皮脂腺癌 (SGC) 的表现和结果。回顾性临床队列研究 方法： • 地点：四级转诊中心 • 研究人群：499 名 SGC 患者的 500 只眼睛 • 干预措施：切除活检、化疗、眼眶切除术 • 主要结局指标：基于 AJCC 预后分期的肿瘤复发、淋巴结转移、全身转移和死亡 结果：SGC 就诊时的平均年龄为57 岁（55 岁；范围：26 至 82 岁）。根据第 8 版 AJCC 分类，肿瘤属于 0 期 (n=13, 3%)、I 期 (n=158, 32%)、II 期 (n=269, 54%)、III 期 (n=48, 9 %) 和 IV (n=12, 2%)。平均随访 26 个月（中位时间 10 个月；范围 <1 至 192 个月），39 例 (10%)、65 例 (65 例) 出现肿瘤复发、淋巴结转移、全身转移和疾病相关死亡。分别有 16%、33 名（8%）和 33 名（8%）患者。各阶段之间的肿瘤复发率没有显着差异（p=0.472）。 Kaplan-Meier 对区域淋巴结转移、全身转移和转移相关死亡的 5 年估计较高，II 期（分别为 12%、11% 和 12%）、III 期（分别为 69%、25% 和与 I 期（分别为 0%、6% 和 6%）相比，IV 期（分别为 70%、100% 和 100%）。 Cox比例分析显示，II期淋巴结转移的风险比（HR）更大（HR，3.498；95% CI，0.200至10.200；p<0.022），III期（HR，95% CI，24.836；8.733至70.631；p<0.022）。 p<0.001）和 IV（HR，53.731；95% CI，15.418 至 187.253；p<0.001），III 期全身转移（HR.13.895；95% CI，3.871 至 49.874；p<0.001）和 IV（ HR，81.465；95% CI，22.267 至 298.051；p<0.001）以及 III 期（HR，9.182；95% CI，2.743 至 30.728；p<0.001）和 IV 期（HR，85.237；95） % CI，25.331 至 287.422；p<0.001），与 I 期相比。第 8 版 AJCC 分类的预后分期可预测眼睑和眼周 SGC 患者的预后，随着分期的进展而恶化。淋巴结和全身转移的高发生率是这些患者死亡的原因。版权所有 © 2024。由 Elsevier Inc. 出版。

To analyze the presentation and outcomes of eyelid and periocular sebaceous gland carcinoma (SGC) based on prognostic stage of the 8th edition of American Joint Committee on Cancer (AJCC) classification.Retrospective clinical cohort study METHODS: • Setting: Quaternary referral center • Study population: 500 eyes of 499 patients with SGC • Intervention: Excisional biopsy, chemotherapy, Orbital exenteration • Main outcome measures: Tumor recurrence, lymph node metastasis, systemic metastasis, and death based on AJCC prognostic staging RESULTS: The mean age at presentation with SGC was 57 years (55 years; range, 26 to 82 years). Based on the 8th edition of AJCC classification, tumors belonged to Stage 0 (n=13, 3%), I (n=158, 32%), II (n=269, 54%), III (n=48, 9%), and IV (n=12, 2%). At a mean follow-up of 26 months (median, 10 months; range, <1 to 192 months), tumor recurrence, lymph node metastasis, systemic metastasis, and disease-related death were seen in 39 (10%), 65 (16%), 33 (8%), and 33 (8%) patients respectively. Tumor recurrence rates did not differ significantly between the stages (p=0.472). The 5-year Kaplan-Meier estimates of regional lymph node metastasis, systemic metastasis, and metastasis-related death were higher for stage II (12%, 11%, and 12%, respectively), III (69%, 25%, and 42%, respectively) and IV (70%, 100%, and 100%, respectively) compared to stage I (0%, 6%, and 6%, respectively). Cox proportional analysis revealed a greater hazard ratio (HR) for lymph node metastasis in stage II (HR, 3.498; 95% CI, 0.200 to 10.200; p<0.022), III (HR, 95% CI, 24.836; 8.733 to 70.631; p<0.001), and IV (HR, 53.731; 95% CI, 15.418 to 187.253; p<0.001), systemic metastasis in stage III (HR. 13.895; 95% CI, 3.871 to 49.874; p<0.001) and IV (HR, 81.465; 95% CI, 22.267 to 298.051; p<0.001) and for disease-related death in stage III (HR, 9.182; 95% CI, 2.743 to 30.728; p<0.001) and IV (HR, 85.237; 95% CI, 25.331 to 287.422; p<0.001), compared to stage I.The prognostic staging of the 8th edition AJCC classification predicts the prognosis of patients with eyelid and periocular SGC, which worsens with the advancing stage. The high incidence of lymph node and systemic metastasis accounts for mortality in these patients.Copyright © 2024. Published by Elsevier Inc.